# Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

> **NCT00002778** · PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 40 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** sargramostim
- **BIOLOGICAL:** therapeutic allogeneic lymphocytes
- **PROCEDURE:** allogeneic bone marrow transplantation
- **PROCEDURE:** in vitro-treated bone marrow transplantation

## Key facts

- **NCT ID:** NCT00002778
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1995-02
- **Primary completion:** 2005-02
- **Final completion:** 2010-07
- **Target enrollment:** 40 (ESTIMATED)
- **Why stopped:** subject accrual and data analysis is completed.
- **Last updated:** 2011-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002778, "Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00002778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*